GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Peptide
Comment: GAL-101 (Galimedix Therapeutics) is a small bioactive peptide that reduces formation of neurotoxic amyloid β 1-42 (Aβ1-42) oligomers [1-3]. GAL-101 binds to aromatic residues in Aβ1-42 recognition interfaces during oligomer assembly and also breaks the protein's β strands [1]. This mechanism is proposed to reduce neuronal damage in Aβ-driven diseases.
|
|
References |
1. Frydman-Marom A, Rechter M, Shefler I, Bram Y, Shalev DE, Gazit E. (2009)
Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies. Angew Chem Int Ed Engl, 48 (11): 1981-6. [PMID:19035593] |
2. Pizzi E, Gornatti S, Stabilini S, Brambilla D, Mercurio CA, Russ H, Parsons CG, Mazzaniti M. (2025)
GAL-101 prevents amyloid beta-induced membrane depolarization in two different types of retinal cells. biorxiv, Preprint. DOI: 10.1101/2025.01.21.634046 |
3. Rammes G, Parsons CG. (2020)
The Aβ aggregation modulator MRZ-99030 prevents and even reverses synaptotoxic effects of Aβ1-42 on LTP even following serial dilution to a 500:1 stoichiometric excess of Aβ1-42, suggesting a beneficial prion-like seeding mechanism. Neuropharmacology, 179: 108267. [PMID:32758564] |